Phase 3 Endometrial Cancer Trial Fails, Karyopharm Pivots to Myelofibrosis
KPTI is trading near its 52-week low of $3.65 (38% below the low) on elevated volume (6.5× avg).
Summary
Karyopharm's Phase 3 trial of selinexor as maintenance therapy in endometrial cancer missed its primary endpoint of progression-free survival. The company is slashing investment in the program and redirecting resources to myelofibrosis and multiple myeloma. Shares crashed to $2.49 after hours, below the prior record low of $3.51, wiping out a 2.1% regular-session gain. This follows a going-concern warning and a cash runway only into late Q3 2026, making the pipeline setback acutely threatening. An sNDA submission for selinexor+ruxolitinib in myelofibrosis is planned for August, now the critical near-term catalyst.
At the time of this announcement, KPTI was trading at $2.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $158.9M. The 52-week trading range was $3.65 to $10.99. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.